Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19058528 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | February 2025 | April 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 18967259 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | December 2024 | June 2025 | Allow | 7 | 2 | 1 | No | No |
| 18948648 | INTERLEUKIN 18 (IL-18) VARIANTS AND FUSION PROTEINS COMPRISING SAME | November 2024 | March 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 18861616 | COLLAGEN HYDROLYSATE COMPOSITION FOR REDUCING JOINT PAIN AFTER EXERCISE | October 2024 | June 2025 | Allow | 7 | 0 | 0 | Yes | No |
| 18929510 | METHODS FOR THE TREATMENT OF THYROID EYE DISEASE | October 2024 | February 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18927301 | PHARMACEUTICAL COMPOSITIONS COMPRISING COLLAGENASE I and COLLAGENASE II | October 2024 | December 2024 | Allow | 2 | 0 | 0 | No | No |
| 18909225 | METHODS OF TREATING OR PREVENTING A CARDIOVASCULAR SYSTEM COMPLICATION OF SICKLE CELL DISEASE WITH AN ANTI-G-CSFR ANTIBODY | October 2024 | April 2025 | Allow | 7 | 1 | 1 | No | No |
| 18901182 | ANTIBODY TARGETING B CELL MATURATION ANTIGEN AND RELATED PRODUCTS THEREOF AND MEDICAL APPLICATIONS | September 2024 | May 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18896718 | ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS | September 2024 | April 2025 | Allow | 7 | 2 | 1 | Yes | No |
| 18896286 | IL-15-BASED FUSIONS TO IL-12 AND IL-18 | September 2024 | December 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18830877 | ANTI IL-6 DOMAIN ANTIBODIES WITH FATTY ACID SUBSTITUENTS | September 2024 | April 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18828243 | EARLY INTERVENTION METHODS TO PREVENT OR AMELIORATE TOXICITY | September 2024 | March 2025 | Allow | 6 | 1 | 0 | No | No |
| 18823573 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | September 2024 | January 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18821708 | METHODS OF CROSSLINKING IgG | August 2024 | May 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18817109 | ANTI-IL-18BP ANTIBODIES | August 2024 | April 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18808126 | ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) METHOD AND MONOCLONAL ANTIBODY FOR GIANT PANDA RELAXIN-3 (RLN3) | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18807825 | APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18804738 | INTERLEUKIN 21 VARIANTS | August 2024 | January 2025 | Allow | 5 | 1 | 0 | No | No |
| 18792080 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION | August 2024 | May 2025 | Abandon | 9 | 1 | 0 | Yes | No |
| 18790955 | ANTI-GPRC5D ANTIBODIES AND COMPOSITIONS | July 2024 | December 2024 | Allow | 4 | 0 | 1 | No | No |
| 18783156 | COAGULATION MOLD, A KIT AND A METHOD FOR PREPARING A COAGULATED BLOOD MASS | July 2024 | June 2025 | Allow | 11 | 0 | 1 | Yes | No |
| 18773461 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | July 2024 | March 2025 | Allow | 8 | 1 | 1 | No | No |
| 18750971 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | June 2024 | September 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18720291 | IL-4 DERIVED PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | June 2024 | April 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18737465 | BCG AND IL-15 BASED MOLECULES | June 2024 | March 2025 | Allow | 9 | 3 | 0 | No | No |
| 18737455 | IL-15-BASED MOLECULES WITH ANTI-CD20 ANTIBODY AND METHODS OF USE | June 2024 | February 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 18732612 | METHOD FOR PREVENTION OR TREATMENT OF DISEASES CAUSED BY PATHOGEN-ASSOCIATED MOLECULAR PATTERN | June 2024 | June 2025 | Abandon | 12 | 1 | 1 | No | No |
| 18679187 | Advanced Avatar Dendritic Cells | May 2024 | October 2024 | Allow | 5 | 1 | 0 | No | No |
| 18671801 | TREATMENT OF INFLAMMATORY CONDITIONS BY DELIVERY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN | May 2024 | October 2024 | Allow | 5 | 1 | 0 | No | No |
| 18656957 | HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATION | May 2024 | April 2025 | Abandon | 11 | 1 | 1 | Yes | No |
| 18656092 | ANTI-SLC34A2 MONOCLONAL ANTIBODIES AND USES THEREOF | May 2024 | September 2024 | Allow | 5 | 0 | 1 | No | No |
| 18656236 | IL23R BINDING MOLECULES AND METHODS OF USE | May 2024 | March 2025 | Abandon | 10 | 0 | 1 | No | No |
| 18650566 | BIOPHARMACEUTICAL COMPOSITIONS | April 2024 | August 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18650526 | BIOPHARMACEUTICAL COMPOSITIONS | April 2024 | August 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18650552 | BIOPHARMACEUTICAL COMPOSITIONS | April 2024 | August 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18639678 | COMPOSITIONS COMPRISING IL-15N72D-BASED MOLECULES AND BACILLUS CALMETTE-GUERIN (BCG) | April 2024 | January 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18630263 | CYTOKINE-BISPHOSPHONATE CONJUGATES | April 2024 | December 2024 | Allow | 8 | 1 | 0 | No | No |
| 18628440 | THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18626591 | Il-2 Mutant And Application Thereof | April 2024 | March 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18615520 | NUCLEIC ACID MOLECULES ENCODING CLOSTRIDIUM HISTOLYTICUM COLLAGENASE I AND METHODS OF PRODUCING THE SAME | March 2024 | June 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18616055 | INTERLEUKIN-2 AGENTS AND USES THEREOF | March 2024 | September 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18610618 | ANTI-GIANT PANDA LIF MONOCLONAL ANTIBODY, and HYBRIDOMA CELL LINE, AND USE THEREOF | March 2024 | November 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18611464 | IL-15-BASED FUSIONS TO IL-12 AND IL-18 | March 2024 | February 2025 | Abandon | 11 | 1 | 1 | Yes | No |
| 18604076 | THERAPEUTIC MOLECULES THAT BIND TO LAG3 AND PD1 | March 2024 | June 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18599583 | FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | March 2024 | September 2024 | Allow | 7 | 2 | 1 | No | No |
| 18595641 | DARIC INTERLEUKIN RECEPTORS | March 2024 | June 2025 | Allow | 16 | 0 | 0 | No | No |
| 18592746 | IL-11 ANTIBODIES | March 2024 | December 2024 | Allow | 9 | 2 | 1 | Yes | No |
| 18583481 | ERBB-2 AND ERBB-3 BINDING BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF CELLS THAT HAVE AN NRG1 FUSION GENE | February 2024 | November 2024 | Allow | 8 | 2 | 0 | No | No |
| 18444463 | COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF GLUCAGON-LIKE PEPTIDE-1 ANALOGS AND USES THEREOF | February 2024 | December 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18441998 | METHODS OF TREATMENT OR PREVENTION OF IMMUNE RESPONSES AND INFLAMMATORY DISEASES WITH ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES | February 2024 | May 2025 | Allow | 15 | 1 | 1 | No | No |
| 18431767 | METHODS OF USING IMMUNOTHERAPEUTICS THAT BIND FOLATE RECEPTOR ALPHA | February 2024 | February 2025 | Allow | 12 | 1 | 1 | No | No |
| 18426199 | HOMODIMERIC ANTIBODIES FOR USE IN TREATING CANCERS AND METHODS OF USE | January 2024 | January 2025 | Allow | 12 | 1 | 1 | No | No |
| 18413753 | AMELIORATION AND TREATMENT OF INFARCTION DAMAGE WITH A POLYPEPTIDE SEGEMENT OF BNIP3 | January 2024 | February 2025 | Allow | 13 | 2 | 1 | Yes | No |
| 18407929 | ACTIVIN RECEPTOR TYPE IIB VARIANTS AND METHODS OF USE THEREOF | January 2024 | December 2024 | Allow | 11 | 0 | 0 | Yes | No |
| 18402604 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | January 2024 | August 2024 | Allow | 7 | 2 | 0 | No | No |
| 18395996 | METHOD OF TREATMENT USING ANTI-CD19 RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS | December 2023 | July 2025 | Allow | 18 | 1 | 0 | No | No |
| 18395108 | ANTIBODY THAT BINDS LPAR1 | December 2023 | July 2024 | Allow | 7 | 1 | 0 | No | No |
| 18395042 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF | December 2023 | November 2024 | Allow | 11 | 1 | 0 | No | No |
| 18390569 | METHODS FOR INDUCING AN IMMUNE RESPONSE BY ADMINISTERING ACTIVATED MESENCHYMAL STEM CELLS | December 2023 | April 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18391146 | METHODS AND COMPOSITIONS FOR REGENERATING TISSUES | December 2023 | December 2024 | Allow | 12 | 0 | 0 | Yes | No |
| 18566391 | HUMANIZED ANTI-CLEC-1A ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF | December 2023 | June 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18514330 | IL12RB1-BINDING MOLECULES AND METHODS OF USE | November 2023 | February 2025 | Abandon | 15 | 1 | 1 | No | No |
| 18508874 | ANTI-PAPP-A ANTIBODIES AND METHODS OF USE THEREOF | November 2023 | July 2024 | Allow | 8 | 1 | 0 | No | No |
| 18505590 | METHOD OF ASSESSING REGULATION OF AN IMMUNE RESPONSE TO AN ADMINISTERED AGENT BY MEASURING ACTIVATION OF NODOSE GANGLION NEURONS | November 2023 | May 2025 | Allow | 19 | 3 | 1 | No | No |
| 18500622 | ANTI-STEM CELL FACTOR ANTIBODIES AND METHODS OF BLOCKING THE INTERACTION BETWEEN SCF AND c-KIT | November 2023 | May 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18498430 | MULTIMERIC IL-15 SOLUBLE FUSION MOLECULES AND METHODS OF MAKING AND USING SAME | October 2023 | April 2025 | Allow | 18 | 0 | 1 | Yes | No |
| 18384035 | COMBINATION OF PVY MONOCLONAL ANTIBODIES CAPABLE OF RECOGNIZING DIFFERENT ANTIGENIC DETERMINANTS, AND USE THEREOF | October 2023 | August 2024 | Allow | 10 | 1 | 1 | No | No |
| 18492150 | MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | October 2023 | July 2024 | Allow | 9 | 0 | 0 | Yes | No |
| 18556606 | ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY | October 2023 | October 2024 | Allow | 12 | 1 | 1 | No | No |
| 18488265 | COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION | October 2023 | June 2025 | Allow | 20 | 1 | 1 | No | No |
| 18555338 | HYPERIMMUNIZED EGG PRODUCT FOR TREATING OR PREVENTING ALCOHOLIC LIVER DISEASE AND GRAFT-VERSUS-HOST DISEASE | October 2023 | May 2025 | Allow | 19 | 2 | 1 | No | No |
| 18485116 | TREATMENT OF CYTOKINE RELEASE SYNDROME WITH GM-CSF ANTAGONISTS | October 2023 | June 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18477113 | COMPOSITIONS COMPRISING ANTI-NRP2 ANTIBODIES | September 2023 | May 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18472053 | IL-15-BASED FUSIONS TO IL-7 AND IL-21 | September 2023 | April 2025 | Allow | 19 | 0 | 1 | Yes | No |
| 18465115 | ANTI-TNFRSF9 ANTIBODIES AND USES THEREOF | September 2023 | May 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18461760 | THERAPEUTIC USES OF ANTI-GITR ANTIBODIES | September 2023 | February 2025 | Allow | 17 | 1 | 0 | Yes | No |
| 18459465 | PROPERDIN BINDING PROTEIN AND USE THEREOF | September 2023 | August 2024 | Allow | 11 | 2 | 1 | Yes | No |
| 18280100 | Methods Of Treating Anemia in Myelodysplastic Syndromes | September 2023 | June 2025 | Allow | 22 | 2 | 1 | Yes | Yes |
| 18279476 | LA PROTEIN AS A NOVEL REGULATOR OF OSTEOCLASTOGENESIS | August 2023 | November 2024 | Abandon | 15 | 1 | 1 | No | No |
| 18457427 | Agonistic Interleiukin 15 Complexes and Uses Thereof | August 2023 | May 2025 | Abandon | 20 | 2 | 1 | Yes | Yes |
| 18458037 | USE OF TLR AGONIST AND ANTI-CD47 AGENT TO ENHANCE PHAGOCYTOSIS OF CANCER CELLS | August 2023 | February 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18457861 | ANTI-ROR2 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF | August 2023 | March 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18238385 | MULTIFUNCTIONAL BTLA EXTRACELLULAR DOMAIN CO-INHIBITORY MOIETY TRAPS TO MODULATE IMMUNE TOLERANCE | August 2023 | February 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18453691 | Antagonistic CD40 Monoclonal Antibodies and Uses Thereof | August 2023 | May 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 16972460 | MULTI-SPECIFIC BINDING PROTEINS AND METHODS OF USE THEREOF | August 2023 | December 2024 | Allow | 48 | 1 | 1 | Yes | No |
| 18366770 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS COMPRISING IL-31 ANTAGONIST AS ACTIVE INGREDIENT | August 2023 | June 2025 | Allow | 22 | 1 | 0 | Yes | No |
| 18364085 | MULTIVALENT BINDING COMPOSITIONS WITH REACTIVE GROUPS | August 2023 | December 2024 | Abandon | 16 | 2 | 1 | Yes | No |
| 18360984 | TAM RECEPTOR-BINDING FUSION MOLECULE HAVING NON-INFLAMMATORY PHAGOCYTOSIS INDUCING ACTIVITY | July 2023 | October 2024 | Allow | 15 | 2 | 1 | Yes | No |
| 18357639 | METHOD OF TREATING DIABETES WITH FGF21 AND GLP1 DOUBLE GENE-MODIFIED CELL | July 2023 | June 2025 | Allow | 22 | 2 | 1 | No | No |
| 18224440 | INTERLEUKIN-2 VARIANTS AND METHODS OF USES THEREOF | July 2023 | July 2024 | Allow | 12 | 2 | 0 | Yes | No |
| 18222763 | BISPECIFIC CD137-BINDING ANTIBODIES FOR T-CELL ACTIVATION | July 2023 | February 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18352769 | SINGLE-CHAIN TRAIL-RECEPTOR AGONIST PROTEINS | July 2023 | December 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18352366 | TUNABLE SILK-BASED BIOMATERIALS WITH SACCHARIDE SUBSTITUTIONS, AND METHODS OF PRODUCING THE SAME | July 2023 | February 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18221206 | SYNTHETIC CELLULAR SIGNALING PATHWAYS AND USES THEREOF | July 2023 | October 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18346250 | CYTOKINE FUSION PROTEINS, AND THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS | July 2023 | April 2025 | Allow | 22 | 0 | 1 | Yes | No |
| 18346205 | HETERODIMERIC RELAXIN FUSIONS AND USES THEREOF | July 2023 | August 2024 | Allow | 14 | 0 | 0 | No | No |
| 18343850 | DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF | June 2023 | February 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18344242 | HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE | June 2023 | April 2025 | Allow | 21 | 0 | 1 | Yes | No |
| 18329308 | NUCLEIC ACIDS ENCODING CLOSTRIDIUM HISTOLYTICUM DELTA TOXIN AND METHODS OF PRODUCING THE SAME | June 2023 | May 2025 | Abandon | 23 | 2 | 0 | No | No |
| 18341404 | METHOD OF REDUCING GLUCOSE INTOLERANCE OR INSULIN RESISTANCE IN A PATIENT IN NEED THEREOF | June 2023 | June 2025 | Allow | 24 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1674.
With a 37.7% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Art Unit 1674 is part of Group 1670 in Technology Center 1600. This art unit has examined 6,270 patent applications in our dataset, with an overall allowance rate of 74.3%. Applications typically reach final disposition in approximately 26 months.
Art Unit 1674's allowance rate of 74.3% places it in the 38% percentile among all USPTO art units. This art unit has a below-average allowance rate compared to other art units.
Applications in Art Unit 1674 receive an average of 1.85 office actions before reaching final disposition (in the 53% percentile). The median prosecution time is 26 months (in the 66% percentile).
When prosecuting applications in this art unit, consider the following:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.